Economic evaluation of Cardiac Contractility Modulation (CCM) therapy with the optimizer IVs in the management of heart failure patients

Heart failure (HF) is a complex clinical syndrome caused by structural and/or functional cardiac disorders that impair the heart’s ability as a pump to support the circulation1-3. It is associated with a broad spectrum of signs and symptoms resulting in a wide range of clinical expressions. Its prevalence is approximately 1-2% of the population and increases rapidly with age, reaching double digits in those above the age of sixty five4-7. Hence, due to the aging of the population and the improved survival of patients presenting with acute coronary syndromes, the number of HF patients is constantly rising. People with HF exhibit high mortality rates and very poor quality of life, both of which are comparable to or even worse than that of many cancer patients. Moreover, HF patients are hospitalized very frequently and they consume significant amount of healthcare resources8-10. Therefore, HF represents a significant cost burden for health systems and a considerable cause of productivity loss for society5-7.